# Questions the Headlines Leave Behind > FAQ — Research Peptide Fundamentals Research Peptides — Peptide Notes — Research Peptide Fundamentals research peptides FAQ: plain answers about GHK-Cu, KPV, semaglutide, tirzepatide, evidence levels, and anecdotal reports. **READER QUESTIONS / CHECKED** Short answers, evidence labels included. Each response follows the strongest supplied source and stops where that source stops. ## What does a GHK-Cu peptide do? GHK-Cu binds copper and has been studied for skin-matrix signaling, collagen-related activity, wound-repair pathways, and topical cosmetic outcomes. Reviews report promising changes in small human topical studies, while laboratory analyses describe broader gene-expression effects [1][2][4]. The limitation is important: skin delivery is difficult, controlled human studies are limited, and systemic benefits have not been validated. ## What is GHK-Cu and how does it work? It is the copper complex of the three-amino-acid peptide glycyl-L-histidyl-L-lysine. The complex can carry copper and influence fibroblasts, the cells that make structural components of skin. Copper also supports enzymes involved in collagen and elastin cross-linking. Those mechanisms explain the research interest; they do not establish every cosmetic or systemic claim made for the ingredient. ## Is GHK-Cu peptide really anti-aging? “Anti-aging” is too broad for the evidence. Small topical studies and reviews report signals involving procollagen, skin texture, and other cosmetic measures [1][4]. A combination hair product also beat placebo in a small trial [3]. None of that demonstrates general slowing or reversal of human aging. The defensible description is a topical skin-research signal with delivery and replication gaps. ## What is the difference between GHK and GHK-Cu? GHK is the three-amino-acid peptide without a bound metal. GHK-Cu is the coordinated complex formed when GHK binds copper. The copper-bound form is central to much of the tissue-remodeling and cosmetic literature. Treating the names as synonyms can obscure which material a study actually tested. ## What is KPV peptide? KPV is lysine-proline-valine, the final three-amino-acid fragment of alpha-melanocyte-stimulating hormone. It is studied as an anti-inflammatory peptide that lacks the full hormone’s pigmentary action [10]. It is not an approved medicine, and the supplied record contains no published human clinical trial. ## What does KPV peptide do? In cells and mice, KPV reduces NF-kB and MAP-kinase signaling and lowers inflammatory cytokine release. It can enter intestinal epithelial cells through the PepT1 short-peptide transporter [8]. Mouse colitis studies report lower inflammation and earlier recovery [9]. Whether those effects translate into safe, effective human treatment remains unknown. ## What is KPV peptide used for? In the research literature, KPV is used to investigate inflammatory signaling and experimental colitis, including targeted nanoparticle delivery to inflamed colon tissue [6][7]. That is a laboratory and preclinical use, not an approved human indication. ## What is semaglutide? Semaglutide is a long-acting GLP-1 receptor agonist: an engineered peptide analogue of a natural gut hormone. It improves glucose-dependent insulin signaling, suppresses inappropriate glucagon, slows gastric emptying, and influences appetite circuits. It is an approved prescription medicine with large human trial programs. ## What is semaglutide used for? Approved semaglutide products are used under prescription for defined indications that include type 2 diabetes and chronic weight management, with certain formulations carrying additional cardiovascular and metabolic indications. This digest focuses on published evidence. In trials, semaglutide reduced weight and major cardiovascular and kidney events in specified populations [12][13][14]. ## How does semaglutide work for weight loss? It activates GLP-1 receptors in appetite-related brain circuits, reduces food intake, and slows gastric emptying. Rodent research maps activity across the hypothalamus and brainstem [16]. Human randomized trials, rather than the mechanism alone, establish the average weight effect [14]. ## What is tirzepatide? Tirzepatide is a long-acting synthetic peptide that activates both GIP and GLP-1 receptors. It is an approved prescription medicine for type 2 diabetes and chronic weight management, with an additional sleep-apnea indication in adults with obesity. The dual design supports glucose-dependent insulin release, lower food intake, and slower gastric emptying [18]. ## How does tirzepatide compare with semaglutide? In a direct seventy-two-week obesity trial, tirzepatide produced greater average weight loss than semaglutide [11]. In a separate type 2 diabetes trial, tirzepatide produced larger average glucose and weight reductions than the studied semaglutide comparator [21]. These findings are specific to the populations, regimens, and endpoints tested; they do not establish universal superiority. --- Peptide Notes is an independent field file on where peptide studies end and reported experience begins—not a clinic, a shop, or medical advice.